Given that Wnt/β‐catenin signaling maintains CSCs,25, 26 we evaluated whether pharmacologic inhibition of Wnt/β‐catenin signaling reduces CSCs in intestinal tumors deficient in Smad4 and p53. Here, TP53 is linked to intestinal neoplasm.